Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labeled ...

The Philippine Society of Nephrology (PSN) awarded Boehringer Ingelheim (Philippines), Inc. the prestigious Presidential Service Award during the Annual Convention Opening Ceremony on April 24, 2025, ...

Ingelheim, Germany, 22 May 2025 – Boehringer Ingelheim today announced that new clinical data from two early-stage trials targeting the signal regulatory protein α (SIRPα) innate immune ...

Ingelheim, Germany, May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a ...

INGELHEIM, Germany, April 2 (Reuters) - Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 revenues, buoyed by diabetes drug ...

Germany’s Boehringer Ingelheim GmbH filed with regulators in the US, China and Europe to sell a new treatment for lung ...

RIDGEFIELD, Conn., May 22, 2025 /PRNewswire/ --Boehringer Ingelheim will present the latest data in its robust oncology pipeline at the 2025 American Society of Clinical Oncology (ASCO ...

The Philippine Society of Nephrology (PSN) awarded Boehringer Ingelheim (Philippines) Inc. the prestigious Presidential ...

The new data from PureTech come after the company reported successful results from the phase 2b Elevate study in December ...

Brian Hilberdink, a pharmaceutical industry veteran, recently assumed the role of President, U.S. Human Pharma, at Boehringer Ingelheim. Hilberdink recently sat down for an informal Q&A on his new ...